Clinical Trial

Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)

Name: Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC) — clinical trial record (NCT07433673)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: GAP Cemi

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is being conducted to find out if treatment with gemcitabine, cisplatin, nab-paclitaxel, and cemiplimab can shrink previously inoperable tumors enough for surgery.

Trial Details

NCT Number	NCT07433673
Lead Sponsor	Columbia University Collaborators: Regeneron Pharmaceuticals
Conditions	Colon and Rectal Cancer
Enrollment	20 participants
Start Date	2026-08
Primary Completion	2028-01 (estimated)
Study Completion	2029-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-25